ストックスクリーナーアプリを入手
9.20
1.32%
0.12
Sage Therapeutics Inc (SAGE) 最新ニュース
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire
H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance
Supernus to acquire Sage Therapeutics stock for $8.50 per share - Investing.com
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
SAGE Stock Update: Truist Securities Raises Price Target | SAGE - GuruFocus
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar
SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada
SAGE: HC Wainwright Maintains Neutral Rating and $12 Price Target | SAGE Stock News - GuruFocus
Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus
Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus
SAGE Stock Rating Maintained as Price Target is Raised by Canacc - GuruFocus
SAGE Price Target Raised Amid Acquisition News | SAGE Stock News - GuruFocus
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone - Benzinga
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com
Piper Sandler Downgrades Sage Therapeutics (SAGE) Following Acqu - GuruFocus
Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine
Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com
Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald
These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's
Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus
Supernus’ $795 million bid sufficient for Sage - The Pharma Letter
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics By Stocktwits - Investing.com India
Supernus enters depression drug market with up to $795 million Sage deal - Reuters
Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating - marketscreener.com
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Benzinga
Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks
Supernus to buy Sage for up to $795 million - Axios
Sage Therapeutics Stock Explodes Over 35% in Massive Rally on Nasdaq - Daily Chhattisgarh News
Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener
Supernus strikes deal to buy Sage Therapeutics - The Business Journals
After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum
SAGE Stock Rating Reiterated as Hold by Needham | SAGE Stock New - GuruFocus
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl
SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada
Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral - marketscreener.com
After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston
Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals
Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus
Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio - MarketScreener
Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition - GuruFocus
Supernus to Acquire Sage Therapeutics (SAGE) for $8.50 Per Share - GuruFocus
Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus
Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):